XORTX Therapeutics Inc. (XRTX)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Peers in Healthcare
XORTX Therapeutics Inc. has no peer companies in this window.
Recent press releases
April 2026
XORTX Therapeutics Conducts Share Offering for Funding
# 🔎 What This Document Is This is a **Post-Effective Amendment** to a registration statement. Think of it as an updated and finalized sales brochure for a fundraising round. XORTX Therapeutics has already filed to sell stock, and this document is the final, official version of the offering details
SEC filings
All filings →Insider trades
All insider trades →XORTX Therapeutics Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at XORTX Therapeutics Inc.
All people →No officers or directors have been indexed for XORTX Therapeutics Inc..